GENE ONLINE|News &
Opinion
Blog

2024-06-26| Asia-Pacific

Taiwan’s Biotech Innovations Draw International Attention at BIO 2024

by Bernice Lottering
Share To
Pei-Li Chen, Deputy Director-General of the Industrial Development Bureau, Ministry of Economic Affairs in her opening speech at the Taiwan Pavilion in US BIO in San Diego this year.

The 2024 BIO International Convention, the world’s largest biotechnology event, took place in San Diego, USA, from June 3 to 6. This year’s convention drew biomedical investors and research experts worldwide. Over 1,500 exhibitors showcased their innovations to more than 19,500 attendees from 70 countries. The Taiwan Pavilion garnered significant attention, holding over 400 meetings in four days and highlighting Taiwan’s rising biotech industry.

Leading Taiwanese Pharmaceutical Companies’ Capabilities Showcased

The 2024 BIO International Convention’s theme was “Time for Science to Shine.” The Taiwan delegation, organized by the Ministry of Economic Affairs (MOEA) Biotechnology and Pharmaceutical Industries Promotion Office, in collaboration with the Ministry of Health and Welfare, Ministry of Agriculture, National Science and Technology Council, National Development Council, Taipei City Government, and the National Biotechnology Research Park. The delegation included over 80 companies and institutions, with around 230 participants.

The delegation focused on new drug development, biotechnology, CDMO (Contract Development and Manufacturing Organization), medical devices, precision medicine, regenerative medicine, agricultural biotechnology, and smart health. International buyers showed strong interest in cancer treatment and CDMO, indicating significant investment potential.

The Taiwan Pavilion featured a CDMO wall showcasing 10 leading Taiwanese pharmaceutical companies’ capabilities. This display highlighted Taiwan’s strengths in intellectual property, regulatory frameworks, and policy support, positioning Taiwan as an ideal partner for international technical and manufacturing collaborations.

Taiwan Pavilion Highlights Pharma Prowess

To strengthen international connections, the Taiwan Pavilion hosted an opening reception and co-organized thematic conferences on cell/gene therapy processes in the Asia-Pacific region and smart innovation digital applications. These efforts aimed to accelerate industry development and foster global integration.

The Taiwan Pavilion’s exhibits featured new drug development projects, including botanical drugs, small molecule drugs, and protein drugs at various stages. They also showcased delivery systems, personalized tumor avatars, organ-on-a-chip technology, universal antibody platforms, cell therapy, and cell culture technologies. Precision and smart medical solutions were highlighted, such as interactive medical 3D imaging, cancer diagnostics, AI physiological monitoring, rapid screening for high-risk neurological diseases, targeted cancer therapies, adhesive patch technology, early cancer screening, and 3D pathological imaging.

Taiwan’s biotech startups also shone on the international stage, with five companies reaching the final round of the BIO Start-Up Stadium competition and attracting global investors’ attention.

In her opening speech at the Taiwan Pavilion, Deputy Director-General of the Industrial Development Bureau, Ministry of Economic Affairs, Pei-Li Chen emphasized the future trend of integrating cross-disciplinary technologies for industrial development. She highlighted Taiwan’s strengths in information and communication technology, comprehensive manufacturing supply chain, and excellent clinical medical capabilities, positioning the country for collaboration with other nations to develop superior biomedical products and services.

The Taiwan Pavilion garnered significant attention, holding over 400 meetings in four days and highlighting Taiwan's rising biotech industry.
At BIO US in San Diego, the Taiwan Pavilion garnered significant attention by holding over 400 meetings in four days, showcasing the rising prominence of Taiwan’s biotech industry.

Major Institutions and Global Partnerships at US BIO

Six major biomedical research institutions from Taiwan, including Academia Sinica, National Health Research Institutes (NHRI), Development Center for Biotechnology (DCB), Industrial Technology Research Institute’s Biomedical Technology and Device Research Laboratories, Pharmaceutical Industry Technology and Development Center (PITDC), and the Agricultural Technology Research Institute (ATRI), showcased their technological achievements in agricultural biotechnology, pharmaceuticals, and medical devices. The Taiwan Bio-Industry Organization introduced the current state of Taiwan’s biotech industry and collaboration opportunities at the Global Innovation Hub event, promoting international partnerships.

During the exhibition, the Taiwan team visited the Phoenix biomedical cluster, including Mayo Clinic’s Barrow Neurological Institute, Translational Genomics Research Institute (TGen), along with Rakuten Medical and Tanvex BioPharma to explore opportunities for joint drug development or production collaboration.

Taiwan Pavilion at BIO US in San Diego: Six major biomedical research institutions from Taiwan showcased their technological achievements in agricultural biotechnology, pharmaceuticals, and medical devices.
Taiwan Pavilion at BIO US in San Diego: Six major biomedical research institutions from Taiwan showcased their technological achievements in agricultural biotechnology, pharmaceuticals, and medical devices.
 
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Thai Biotech Industry’s Promising Potential: Taiwan Works Toward Strengthening APAC Ties at Bio Asia Pacific—Collaboration is Key
2024-09-24
Apple’s AirPods Pro 2: First Ever FDA-approved OTC Hearing Aid Technology
2024-09-20
LATEST
Generative AI Makes its Debut in Smart Healthcare with NVIDIA Experts at the Helm
2024-10-04
TCELS’s Path to a Self-Sufficient Biotech Thailand: Entrepreneurs in Global Competitiveness, Raw Material Exports, and Cosmetic Innovations
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
Immunai and AstraZeneca’s $18 Million AI Collaboration to Transform Cancer Drug Development
2024-09-26
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top